Printer Friendly

CYTOGEN ANNOUNCES FIRST SHIPMENT OF ONCOSCINT CR/OV

 PRINCETON, N.J., Jan. 18 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today that they began shipping commercial quantities of OncoScint CR/OV, its monoclonal antibody-based diagnostic imaging agent for colorectal and ovarian cancer, to its co-promotion partner, Knoll Pharmaceuticals, a Division of BASF K&F Corporation, for national distribution. The first shipment left CYTOGEN's Princeton facility on Friday, Jan. 15, 1993.
 In commenting on this development, George W. Ebright, Chairman and CEO, said "CYTOGEN's success in developing the world's first monoclonal antibody-based product is a tribute to the long-term efforts of CYTOGEN's dedicated employees. At a time when other biotechnology companies are having difficulties developing products, it is very rewarding to be among the few companies that are succeeding.
 On Dec. 30, 1992, the Food and Drug Administration granted marketing approval for OncoScint CR/OV, indicated for determining the extent and location of extrahepatic malignant disease in patients with known colorectal or ovarian cancer.
 CYTOGEN is a biopharmaceutical company engaged in the development of products utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 1/18/93
 /CONTACT: Martin D. Cleary or Mary Beals of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU:

MJ -- PH010 -- 5887 01/18/93 12:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:236
Previous Article:COLUMBIA NATURAL GAS-POWERED BUS USED IN CLINTON/GORE INAUGURATION
Next Article:DAVID D. LELAND NAMED CHAIRMAN OF PLUM CREEK
Topics:


Related Articles
FDA APPROVES CYTOGEN PRODUCT AS FIRST MAB-BASED CANCER IMAGING AGENT IN THE UNITED STATES
CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH
CYTOGEN ENTERS AGREEMENTS TO RAISE $9.4 MILLION
ONCOSCINT(R) CR103 REPEAT ADMINISTRATION AMENDMENT RECOMMENDED FOR APPROVAL IN EUROPE
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN CORPORATION ANNOUNCES UPDATE ON FIRST QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
DR. ROBERT MAGUIRE PROMOTED TO CYTOGEN VP OF MEDICAL AFFAIRS
CYTOGEN UPDATES STOCKHOLDERS ON RECENT BUSINESS DEVELOPMENTS AND THIRD QUARTER FINANCIAL RESULTS
Cytogen Postpones Follow-on Public Offering.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters